Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

mTOR inhibitors vs chemotherapy/hormone therapy

Overall survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.06 [0.7, 1.61]
1 study · 130 participants
Low